FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Advanced Breast Cancer
Clinical Summary:
-
Regulatory Update: The FDA has approved giredestrant plus everolimus for patients with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease recurred during or after adjuvant endocrine-based therapy or progressed following at least 1 endocrine-based regimen in the metastatic setting.
-
Key Outcomes: The approval was supported by results from the evERA Breast Cancer trial, in which giredestrant plus everolimus significantly improved progression-free survival compared with physician-selected endocrine therapy plus everolimus in patients with ESR1-mutated disease, reducing the risk of progression or death by 62%.
-
Clinical Relevance: This approval introduces an oral endocrine-based combination for patients with previously treated ESR1-mutated advanced breast cancer, reinforcing the importance of molecular testing to guide treatment selection following endocrine therapy.
On November 16, 2026, the US Food and Drug Administration (FDA) approved giredestrant (Wilserdly; Genentech) in combination with everolimus for patients with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease recurred during or after endocrine-based adjuvant therapy or progressed following at least 1 endocrine-based regimen in the metastatic setting, introducing an oral endocrine-based treatment option for this biomarker-defined population.
The approval was supported by findings from the multicenter, open-label evERA Breast Cancer trial, which randomized 373 patients to receive either 30 mg of once daily giredestrant (n = 183) or physician-selected endocrine therapy (n = 190), consisting of exemestane, fulvestrant, or tamoxifen. Patients in both treatment arms also received 10 mg of once daily everolimus.
Among the overall study population, 207 patients had ESR1-mutated tumors. Mutation status was determined centrally using ctDNA testing with the FoundationOne Liquid CDx assay, assessing specified ESR1 mutations within the ligand-binding domain.
Premenopausal and perimenopausal women received a gonadotropin-releasing hormone (GnRH) agonist for ovarian function suppression. Male patients also received a GnRH agonist unless they had undergone bilateral orchiectomy. Treatment continued until disease progression or unacceptable toxicity.
The primary efficacy end point was investigator-assessed progression-free survival (PFS) according to RECIST version 1.1. Additional efficacy end points included overall survival (OS) and objective response rate (ORR).
Among patients with ESR1-mutated disease, median PFS was 10 months in the giredestrant plus everolimus arm and 5.5 months in the physician-selected endocrine therapy plus everolimus arm, reducing the risk of disease progression or death by 62% (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27 to 0.54; P < .0001).
The ORR was 27% in the giredestrant plus everolimus arm and 14% in the physician-selected endocrine therapy plus everolimus arm. OS data remained immature at the time of analysis.
The most common adverse reactions, occurring in at least 20% of patients receiving giredestrant plus everolimus, included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea.
Common laboratory abnormalities included decreased hemoglobin, lymphocytes, white blood cell count, neutrophils, platelets, calcium, potassium, and sodium, as well as increased aspartate aminotransferase, alanine aminotransferase, and creatinine.
The recommended dose of giredestrant is 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Everolimus dosing should follow its prescribing information.
The prescribing information includes warnings and precautions for bradycardia and embryo-fetal toxicity.
The FDA also authorized FoundationOne Liquid CDx as a companion diagnostic assay to identify patients with ESR1-mutated breast cancer who may be eligible for giredestrant plus everolimus.
This approval expands targeted endocrine treatment options for patients with ESR1-mutated advanced breast cancer, supporting the use of ctDNA-based molecular testing to identify eligible patients following progression on endocrine-based therapy.
Source:
US Food and Drug Administration. FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. Accessed on: November 16, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-approves-giredestrant-combination-everolimus-er-positive-her2-negative-esr1-mutated-locally


